Gut Microbiome and Plasma Microbiome-Related Metabolites in Patients With Decompensated and Compensated Heart Failure

DOI HANDLE Web Site Web Site PubMed 14 Citations 44 References Open Access
  • Hayashi Tomohiro
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Yamashita Tomoya
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Watanabe Hikaru
    School of Life Science and Technology, Tokyo Institute of Technology
  • Kami Kenjiro
    Human Metabolome Technologies
  • Yoshida Naofumi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Tabata Tokiko
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Emoto Takuo
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Sasaki Naoto
    Department of Medical Pharmaceutics, Kobe Pharmaceutical University
  • Mizoguchi Taiji
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Irino Yasuhiro
    Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
  • Toh Ryuji
    Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
  • Shinohara Masakazu
    Division of Epidemiology and The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine
  • Okada Yuko
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Ogawa Wataru
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
  • Yamada Takuji
    School of Life Science and Technology, Tokyo Institute of Technology
  • Hirata Ken-ichi
    Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine

Search this article

Abstract

<p>Background: Gut microbiome composition or circulating microbiome-related metabolites in patients with heart failure (HF) have not been investigated at different time points (i.e., in the decompensated (Decomp) and compensated (Comp) phases). </p><p>Methods and Results: We prospectively enrolled 22 patients admitted for HF and 11 age-, sex-, and comorbidity-matched hospitalized control subjects without a history of HF. Gut flora and plasma microbiome-related metabolites were evaluated by amplicon sequencing of the bacterial 16S ribosomal RNA gene and capillary electrophoresis time-of-flight mass spectrometry, respectively. HF patients were evaluated in both the Decomp and Comp phases during hospitalization. The phylum Actinobacteria was enriched in HF patients compared with control subjects. At the genus level, Bifiodobacterium was abundant while Megamonas was depleted in HF patients. Meanwhile, plasma concentration of trimethylamine N-oxide (TMAO), a gut microbiome-derived metabolite, was increased in HF patients (Decomp HF vs. control, P=0.003; Comp HF vs. control, P=0.004). A correlation analysis revealed positive correlations between the abundance of the genus Escherichia/Shigella and levels of TMAO and indoxyl sulfate (IS, a microbe-dependent uremic toxin) in Comp HF (TMAO: r=0.62, P=0.002; IS: r=0.63, P=0.002). Escherichia/Shigella was more abundant in Decomp than in Comp HF (P=0.030). </p><p>Conclusions: Our results suggest that gut microbiome composition and microbiome-related metabolites are altered in HF patients. </p>

Journal

  • Circulation Journal

    Circulation Journal 83 (1), 182-192, 2018-12-25

    The Japanese Circulation Society

Citations (14)*help

See more

References(44)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top